

a2 4. (Once Amended) The formulation of claim 3 wherein the fatty acid-acylated insulin is N-palmitoyl Lys<sup>B29</sup> human insulin and the ~~solution~~ contains [at least about 0.3 to 0.55] from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

a3 13. (Once Amended) A storage stable insulin formulation comprising an aqueous solution of a fatty acid-acylated insulin analog containing [at least about 0.2 to 0.7] from about 0.2 mole to about 0.7 mole of zinc per mole of said fatty acid-acylated insulin and having a pH of 6.8 to 7.8.

a4 16. (Once Amended) The formulation of claim ~~15~~ wherein the fatty acid-acylated insulin is B28-N<sup>E</sup>-palmitoyl-Lys<sup>B28</sup>Pro<sup>B29</sup>-human ~~insulin~~ and the solution contains [at least about 0.3 to 0.55] from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

#### REMARKS

Claims 1, 4, 13 and 16 have been amended consistent with the language on page 8 of the application concerning the level zinc in the inventive compositions. No new matter has been added.

**BEST AVAILABLE COPY**

Item 1 in the Office Action mistakenly indicates that only claims 12-26 are pending. This was apparently a typographical error since the Office Action acts on all of the pending claims 1-26.

Claims 1-26 stand rejected under 35 U.S.C. §112, second paragraph, as being indefinite. This rejection is respectfully traversed.

Claims 1, 4, 13 and 16 have been amended. The amended language is consistent with the specification at page 8 and overcomes the rejection. The language used in the amended claims is widely used and understood in defining concentration ranges in this technology. See, for